Warhound Secures $200M Valuation to Engineer U.S. Military Workforce

A $1.2 billion valuation signals a major shift in how the U.S. defense sector procures biological assets. Warhound has emerged from stealth mode with $200 million in new capital, a round led by Sequoia, 8VC, Corner Ventures, and In-Q-Tel. The venture firm, which is backed by the CIA and other U.S. intelligence agencies, joins the investor roster to support a company dedicated to genetically engineering dogs for military, law enforcement, and emergency response roles. The funding marks a significant bet on biotechnology as a solution to a persistent logistical bottleneck in defense operations.

The conflict driving this investment is a shrinking domestic supply of capable working dogs. According to the company’s launch materials, more than 80% of the U.S. military’s working dogs are currently sourced from Europe. Furthermore, less than half of these imported animals are deemed fit for service upon arrival. This reliance on foreign supply chains exposes the U.S. to potential disruptions and quality control issues, prompting Warhound to develop a domestic, engineered alternative.

The company’s strategy stems from a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. The two founders met approximately a year ago at a conference, where discussions centered on the inadequacies of current breeding practices. Lamm noted that many working dogs fail to complete training due to inherited health issues, including poor eyesight, high cancer risks, hip dysplasia, and muscle atrophy. This realization drove the development of a biobank containing cell lines from high-performing breeds, specifically the Belgian Malinois and German Shepherd.

Warhound’s technical approach involves editing the genes of these breeds to create a new type of dog optimized for demanding missions. The goal is to enhance characteristics such as speed, agility, and olfactory sensitivity for tasks like bomb detection. The company aims to remove genetic predispositions to health problems while adding traits that improve performance and longevity. This process moves beyond traditional selective breeding, utilizing precise genetic modification to engineer specific capabilities.

Anduril, a key partner in the venture, will provide the hardware and software layer for these animals. This includes protection vests and goggles designed to aid situational awareness for both the dogs and their handlers. Lamm described the concept as adding technology "on top of the dog, not in the dog." For instance, vests equipped with data sensors can transmit real-time information to handlers, improving coordination and safety during high-risk operations. Luckey serves as a partner in the venture but holds no equity, while Colossal Biosciences retains equity and licenses its underlying technology to Warhound.

The production timeline is aggressive. The first batch of dogs is currently being cloned and incubated, with births expected in early 2027. The company aims to have these animals in service within two years. Viagen, another company owned by Colossal, will handle the cloning process, leveraging a technology with a high success rate that is already used in Colossal’s endangered species programs. Although pricing has not yet been established, Warhound expects to sell to first responders, the Department of Defense, various military service groups, and police forces.

Regulatory and ethical oversight remains a focal point. Warhound stated it has briefed numerous government groups on its business model. To address civilian safety concerns, the company noted that each dog will undergo standard military working dog training and will be managed by the purchasing agency. Additionally, the American Humane Society is guiding the certification of Warhound’s training program. The Society also aims to integrate retired Warhound dogs into its Military Working Dog Reunification Program, which finds homes for retired service animals. The organization stated it applauds Warhound and Colossal for inviting a science and ethics-focused partner to the table to ensure the animals are treated humanely.